PMDA drug package insert
ノイトロジン注50μg
PMDA Prescription drug · 中外製薬株式会社 · package insert Oct 13, 2023
Key facts
| Brand names | ノイトロジン注50μg, ノイトロジン注100μg, ノイトロジン注250μg |
|---|---|
| Nonproprietary names | レノグラスチム（遺伝子組換え） |
| Companies | 製造販売元／中外製薬株式会社 |
| Product type | Prescription drug |
| Therapeutic category | 遺伝子組換えヒトG-CSF製剤 |
| Therapeutic category codes | 873399 |
| YJ codes | 3399406D4027, 3399406D5023, 3399406D6020 |
| Approval numbers | 20300AMZ00758, 20300AMZ00759, 20300AMZ00760 |
| Package insert edition | 第4版 |
| Package insert date | Oct 13, 2023 |
| PMDA document key | 450045_3399406D4027_1 |
| PMDA company code | 450045 |
At a glance
- 1–9 Package insert revisions
- 10–99 Related PMDA documents
- None Safety communications
- Yes PMDA review report published
- No Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: